ANON2
MCID: ANR007
MIFTS: 61

Anorexia Nervosa (ANON2) malady

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Anorexia Nervosa

Aliases & Descriptions for Anorexia Nervosa:

Name: Anorexia Nervosa 54 12 52 42 14 69
Bulimia Nervosa 2 66 29
Bulimia Nervosa 42 69
Anorexia Nervosa, Susceptibility to 13
Anorexia Nervosa 2 66
Anon2 66
Buln2 66

Classifications:



External Ids:

OMIM 54 610269
Disease Ontology 12 DOID:8689
ICD10 33 F50.0 F50.00
ICD9CM 35 307.1
NCIt 47 C34387
UMLS 69 C0003125

Summaries for Anorexia Nervosa

UniProtKB/Swiss-Prot : 66 Anorexia nervosa 2: An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea. Bulimia nervosa 2: A psychiatric disorder characterized by eating an unusually large amount of food in a short period of time, followed by inappropriate acts (purging) to avert weight gain. Compensatory behavior includes self-induced vomiting, laxative abuse, and excessive exercise.

MalaCards based summary : Anorexia Nervosa, also known as bulimia nervosa 2, is related to body dysmorphic disorder and hypoglycemic coma. An important gene associated with Anorexia Nervosa is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are Peptide ligand-binding receptors and Prolactin Signaling Pathway. The drugs Dopamine and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

OMIM : 54 For a phenotypic description and a discussion of heterogeneity of susceptibility to bulimia nervosa, see 607499. For a... (610269) more...

Wikipedia : 71 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by a low... more...

Related Diseases for Anorexia Nervosa

Diseases in the Anorexia Nervosa family:

Anorexia Nervosa 1

Diseases related to Anorexia Nervosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 280)
id Related Disease Score Top Affiliating Genes
1 body dysmorphic disorder 31.5 ADIPOQ GHRL IGF1 LEP LEPR NPY
2 hypoglycemic coma 30.0 BDNF CRH HTR2A SLC6A4
3 hypoglycemia 29.9 BDNF CRH POMC SLC6A4
4 limb ischemia 29.6 ADIPOQ HTR2A IGF1 LEP LEPR
5 personality disorder 29.6 BDNF CCK COMT CRH HTR2A POMC
6 autism spectrum disorder 29.5 BDNF CCK COMT GHRL POMC SLC6A4
7 schizophrenia 29.4 BDNF CCK COMT HTR2A NPY PRL
8 anorexia nervosa 1 12.5
9 eating disorder 11.6
10 pili torti 11.3
11 bulimia nervosa 10.7
12 obesity 10.5
13 amenorrhea 10.4
14 vaginal adenoma 10.3 IGF1 POMC
15 grin2a-related speech disorders and epilepsy 10.3 GH1 PRL
16 cleft lip palate-tetraphocomelia 10.3 LEP POMC
17 epidural spinal canal meningioma 10.3 IGF1 LEP PRL
18 gastric dilatation 10.3
19 hypophosphatemia 10.3
20 osseous heteroplasia, progressive 10.3 GH1 IGF1 PRL
21 bone benign neoplasm 10.3 IGF1 POMC PRL
22 papillary craniopharyngioma 10.2 GHRL IGF1 PRL
23 axial osteomalacia 10.2 GH1 IGF1 PRL
24 rickets 10.2 CCK IGF1 PYY
25 congenital tricuspid stenosis 10.2 GH1 POMC PRL
26 olfactory nerve neoplasm 10.2 GH1 POMC PRL
27 central nervous system leiomyoma 10.2 GHRL IGF1 LEP
28 luxation of globe 10.2 NPY PRL SLC6A4
29 dyspepsia 10.2 CCK NPY PRL
30 pelvic muscle wasting 10.2 IGF1 POMC PRL
31 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.2 CCK GHRL PYY
32 primary biliary cirrhosis 10.2 GHRL IGF1 LEP PRL
33 obsessive-compulsive disorder 10.2
34 postencephalitic parkinson disease 10.2 BDNF HTR2A SLC6A4
35 cerebral hemisphere lipoma 10.2 GH1 PRL
36 aflatoxins-related hepatocellular carcinoma 10.2 IGF1 POMC PRL
37 glomangiomyoma 10.2 GH1 GHRL LEP PRL
38 ornithosis 10.2 CCK PRL SLC6A4
39 transmitted_by 10.2 POMC PRL SLC6A4
40 mandibular cancer 10.2 CCK GHRL SLC6A4
41 african histoplasmosis 10.2 POMC PRL
42 caudal regression syndrome 10.2 GH1 IGF1 POMC PRL
43 rheumatic encephalitis 10.2 GH1 IGF1 POMC PRL
44 bile acid synthesis defect, congenital, 4 10.2 GH1 IGF1 POMC PRL
45 cold-induced sweating syndrome 2 10.2 GH1 IGF1 POMC PRL
46 exophthalmic ophthalmoplegia 10.2 ADIPOQ LEP LEPR
47 acrocephalopolydactyly 10.2 ADIPOQ LEP RETN
48 sweat gland cancer 10.2 CCK PYY SLC6A4
49 malignant perineurioma 10.2 ADIPOQ LEP RETN
50 urea cycle disorder 10.2 BDNF COMT IGF1

Comorbidity relations with Anorexia Nervosa via Phenotypic Disease Network (PDN):


Acute Cystitis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Anorexia Nervosa:



Diseases related to Anorexia Nervosa

Symptoms & Phenotypes for Anorexia Nervosa

Clinical features from OMIM:

610269

MGI Mouse Phenotypes related to Anorexia Nervosa:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.43 NPY POMC PRL PYY SLC6A4 CCK
2 homeostasis/metabolism MP:0005376 10.43 ADIPOQ AGRP BDNF CCK COMT CRH
3 endocrine/exocrine gland MP:0005379 10.39 GHRL HTR2A IGF1 LEP LEPR POMC
4 adipose tissue MP:0005375 10.31 ADIPOQ AGRP CRH GHR GHRL IGF1
5 growth/size/body region MP:0005378 10.31 ADIPOQ AGRP BDNF CRH GHR GHRH
6 nervous system MP:0003631 10.24 COMT CRH GHR GHRH IGF1 LEP
7 immune system MP:0005387 10.2 GHRH IGF1 LEP LEPR POMC PRL
8 liver/biliary system MP:0005370 10.14 ADIPOQ AGRP CRH GHR GHRH LEP
9 integument MP:0010771 10.13 PRL SLC6A4 ADIPOQ BDNF CRH GHR
10 normal MP:0002873 9.97 AGRP BDNF CRH GHRL IGF1 LEPR
11 renal/urinary system MP:0005367 9.91 ADIPOQ COMT CRH GHR IGF1 LEP
12 reproductive system MP:0005389 9.81 AGRP BDNF COMT GHR GHRH IGF1
13 respiratory system MP:0005388 9.5 IGF1 LEP LEPR ADIPOQ BDNF COMT
14 skeleton MP:0005390 9.28 ADIPOQ CRH GHR HTR2A IGF1 LEP

Drugs & Therapeutics for Anorexia Nervosa

Drugs for Anorexia Nervosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
3
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
7
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
8 Antipsychotic Agents Phase 4,Phase 3,Phase 2
9 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
10 Dopamine Agents Phase 4
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
12 Psychotropic Drugs Phase 4,Phase 3,Phase 2
13
Serotonin Phase 4,Phase 3,Phase 2 50-67-9 5202
14 Serotonin Agents Phase 4,Phase 3,Phase 2
15 Tranquilizing Agents Phase 4,Phase 3,Phase 2
16 Antiemetics Phase 4,Phase 3,Phase 2
17 Autonomic Agents Phase 4,Phase 3,Phase 2
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
19 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
21 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
22 Antidepressive Agents Phase 4
23 Adrenergic Agents Phase 4
24 Dopamine Antagonists Phase 4
25 Serotonin Antagonists Phase 4
26 Antidepressive Agents, Second-Generation Phase 4
27 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
28 Cytochrome P-450 Enzyme Inhibitors Phase 4
29 Central Nervous System Stimulants Phase 4
30 Dopamine Uptake Inhibitors Phase 4
31 Raclopride Phase 4 84225-95-6
32
Teriparatide Approved, Investigational Phase 3,Phase 2 52232-67-4 16133850
33
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3, Phase 1 50-28-2 5757 53477783
34
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
35
Medroxyprogesterone acetate Approved, Investigational Phase 2, Phase 3,Phase 1 71-58-9
36
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
37
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
38
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7, 17489-40-6 13109
39
Etidronic acid Approved Phase 2, Phase 3 7414-83-7, 2809-21-4 3305
40
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
41
Testosterone Approved, Investigational Phase 2, Phase 3 58-22-0 6013
42
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078 2978
43
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
44
Denosumab Approved Phase 3 615258-40-7
45
Dehydroepiandrosterone Approved, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
46 tannic acid Approved, Nutraceutical Phase 3
47 Bone Density Conservation Agents Phase 3,Phase 2
48 Analgesics Phase 3
49 Vitamins Phase 3
50 Antineoplastic Agents, Hormonal Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 191)
id Name Status NCT ID Phase
1 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4
2 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4
3 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4
4 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4
5 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4
6 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4
7 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3
8 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3
10 Effects of Anorexia Nervosa on Bone Mass in Adolescents Completed NCT00088153 Phase 2, Phase 3
11 Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
12 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
13 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3
14 Bone Loss in Women With Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3
15 The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa Completed NCT02004288 Phase 2, Phase 3
16 Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3
17 Hormonal Therapy for Teens With Anorexia Nervosa Completed NCT01343771 Phase 3
18 Effects of Anorexia Nervosa on Peak Bone Mass Recruiting NCT01301183 Phase 3
19 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Recruiting NCT02567279 Phase 3
20 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Recruiting NCT01626833 Phase 2, Phase 3
21 Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients Recruiting NCT02359123 Phase 3
22 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3
23 Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Unknown status NCT01761942 Phase 2
24 Therapeutic Effects of Neurofeedback in Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
25 A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
26 Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2
27 Treatment for Young Adults With Anorexia Nervosa Completed NCT01190423 Phase 1, Phase 2
28 Olanzapine in the Treatment of Patients With Anorexia Nervosa Completed NCT00260962 Phase 2
29 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2
30 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa Completed NCT00692185 Phase 2
31 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2
32 Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Completed NCT00183586 Phase 2
33 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa Completed NCT00283595 Phase 2
34 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2
35 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed NCT00320567 Phase 2
36 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2
37 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
38 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa Recruiting NCT01611220 Phase 2
39 Treatment of Anxiety and Anorexia Nervosa in Adolescents Recruiting NCT01933243 Phase 2
40 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Recruiting NCT02475265 Phase 2
41 Estrogen Replacement in Anorexia Nervosa Recruiting NCT03172533 Phase 2
42 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2
43 The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2
44 Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01476540 Phase 1
45 Funen Anorexia Nervosa Study - Retrospective Cohort Study and 10 Year Follow-up Study Unknown status NCT00267228 Phase 1
46 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01678014 Phase 1
47 Yoga in Treatment of Eating Disorders Unknown status NCT00870753 Phase 1
48 Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa Completed NCT00601822 Phase 1
49 Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1
50 Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa Completed NCT00149786 Phase 1

Search NIH Clinical Center for Anorexia Nervosa

Cochrane evidence based reviews: anorexia nervosa

Genetic Tests for Anorexia Nervosa

Genetic tests related to Anorexia Nervosa:

id Genetic test Affiliating Genes
1 Bulimia Nervosa 2 29

Anatomical Context for Anorexia Nervosa

MalaCards organs/tissues related to Anorexia Nervosa:

39
Bone, Brain, Heart, Pituitary, Testes, Liver, Thyroid

Publications for Anorexia Nervosa

Articles related to Anorexia Nervosa:

(show top 50) (show all 1332)
id Title Authors Year
1
Differences in Neural Responses to Reward and Punishment Processing between Anorexia Nervosa Subtypes: An fMRI Study. ( 28459134 )
2017
2
A comparison of the metabolic complications and hospital course of severe anorexia nervosa by binge-purge and restricting subtypes. ( 28060579 )
2017
3
Anorexia Nervosa/Atypical Anorexia Nervosa. ( 28532965 )
2017
4
Adequacy of nutrient intake in women with restrictive anorexia nervosa. ( 28526387 )
2017
5
Reexamining the Role of Electroconvulsive Therapy in Anorexia Nervosa in Adolescents. ( 28471772 )
2017
6
Acute retropharyngeal abscess in a patient with anorexia nervosa. ( 28058633 )
2017
7
Deep brain stimulation in the bed nucleus of the stria terminalis and medial forebrain bundle in a patient with major depressive disorder and anorexia nervosa. ( 28469875 )
2017
8
A focus on reward in anorexia nervosa through the lens of the activity-based anorexia (ABA) rodent model. ( 28475260 )
2017
9
Food portion size area mediates energy effects on expected anxiety in anorexia nervosa. ( 28089925 )
2017
10
Effects of Anorexia Nervosa on the Endocrine System. ( 28508601 )
2017
11
Commentary: Atypical Self-Focus Effect on Interoceptive Accuracy in Anorexia Nervosa. ( 28529480 )
2017
12
Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. ( 28494655 )
2017
13
Anorexia nervosa of the restrictive type and celiac disease in adolescence. ( 28496327 )
2017
14
Serum kisspeptin concentrations are negatively correlated with body mass index in adolescents with anorexia nervosa and amenorrhea. ( 28500826 )
2017
15
An Adolescent Male With Anorexia Nervosa Favorably Responded to Mirtazapine. ( 28504977 )
2017
16
Anxiolytic effect of warmth in anorexia nervosa. ( 28043086 )
2017
17
Computerized assessment of body image in anorexia nervosa and bulimia nervosa: comparison with standardized body image assessment tool. ( 27796596 )
2017
18
Plasma BDNF levels and anxiety in women with recovery from anorexia nervosa. ( 28522315 )
2017
19
Body composition in men with anorexia nervosa: Longitudinal study. ( 28457012 )
2017
20
Influence of visceral interoceptive experience on the brain's response to food images in anorexia nervosa. ( 28498277 )
2017
21
Outcomes of an inpatient refeeding protocol in youth with anorexia nervosa: Rady Children's Hospital San Diego/University of California, San Diego. ( 28053702 )
2017
22
Metasynthesis of the Views about Treatment of Anorexia Nervosa in Adolescents: Perspectives of Adolescents, Parents, and Professionals. ( 28056106 )
2017
23
Ammonium acid urate urolithiasis in anorexia nervosa: a case report and literature review. ( 28469876 )
2017
24
Comparing effects: a reanalysis of two studies on season of birth bias in anorexia nervosa. ( 28078085 )
2017
25
Heightened Olfactory Sensitivity in Young Females with Recent-Onset Anorexia Nervosa and Recovered Individuals. ( 28060877 )
2017
26
The role of pride in women with anorexia nervosa: A grounded theory study. ( 28467686 )
2017
27
Relationship of body weight with gastrointestinal motor and sensory function: studies in anorexia nervosa and obesity. ( 28056812 )
2017
28
Lesson of the month 2: A choroid plexus papilloma manifesting as anorexia nervosa in an adult. ( 28365635 )
2017
29
Affective temperaments in anorexia nervosa: The relevance of depressive and anxious traits. ( 28456073 )
2017
30
Assessment of Sex Differences in Body Composition Among Adolescents With Anorexia Nervosa. ( 28087266 )
2017
31
Fifty years of anorexia nervosa and other eating disorders in the Australian & New Zealand Journal of Psychiatry. ( 28521537 )
2017
32
Assessment of sex differences in bone deficits among adolescents with anorexia nervosa. ( 27611361 )
2016
33
Meaningful Memory in Acute Anorexia Nervosa Patients-Comparing Recall, Learning, and Recognition of Semantically Related and Semantically Unrelated Word Stimuli. ( 28032373 )
2016
34
Impaired social cognition processes in Asperger syndrome and anorexia nervosa. In search for endophenotypes of social cognition. ( 27556112 )
2016
35
Persistent amenorrhea and decreased DHEAS to cortisol ratio after recovery from anorexia nervosa. ( 27910716 )
2016
36
Postmortem Diagnosis of Anorexia Nervosa: An Endocrinological and Immunohistochemical Approach. ( 27644577 )
2016
37
Appearance evaluation of others' faces and bodies in anorexia nervosa and body dysmorphic disorder. ( 27566987 )
2016
38
Alexithymia, empathy, emotion identification and social inference in anorexia nervosa: A case-control study. ( 27086047 )
2016
39
White matter microstructural changes in adolescent anorexia nervosa including an exploratory longitudinal study. ( 27182488 )
2016
40
Anorexia nervosa hyperactivity-induced ischemic colitis (ANHIC): a new cause of anaemia. ( 27314583 )
2016
41
Reexpansion pulmonary edema after surgery for spontaneous pneumothorax in a patient with anorexia nervosa. ( 27158490 )
2016
42
Interleukin-7 Plasma Levels in Human Differentiate Anorexia Nervosa, Constitutional Thinness and Healthy Obesity. ( 27611669 )
2016
43
Factors impacting treatment and recovery in Anorexia Nervosa: qualitative findings from an online questionnaire. ( 27195122 )
2016
44
Brain morphological changes in adolescent and adult patients with anorexia nervosa. ( 27188331 )
2016
45
Phosphate Supplementation During Refeeding of Hospitalized Adolescents With Anorexia Nervosa-Watch and Wait or Empirically Treat. ( 27210006 )
2016
46
Vaspin and selected indices of bone status in girls with anorexia nervosa. ( 28042653 )
2016
47
The Intersession Process in Psychotherapy for Anorexia Nervosa: Characteristics and Relation to Outcome. ( 27199179 )
2016
48
Pneumothorax in a young man with anorexia nervosa. ( 27196534 )
2016
49
Altered exposure-related reshaping of body appreciation in adolescent patients with anorexia nervosa. ( 27664532 )
2016
50
Outcomes of an inpatient refeeding protocol in youth with Anorexia Nervosa and atypical Anorexia Nervosa at Children's Hospitals and Clinics of Minnesota. ( 28018595 )
2016

Variations for Anorexia Nervosa

ClinVar genetic disease variations for Anorexia Nervosa:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 BDNF NM_170735.5(BDNF): c.196G> A (p.Val66Met) single nucleotide variant protective,risk factor rs6265 GRCh37 Chromosome 11, 27679916: 27679916

Expression for Anorexia Nervosa

Search GEO for disease gene expression data for Anorexia Nervosa.

Pathways for Anorexia Nervosa

Pathways related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 14)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 CCK CRH GH1 GHR GHRH GHRL
2
Show member pathways
12.29 GH1 LEP LEPR PRL
3
Show member pathways
12.23 ADIPOQ IGF1 LEP LEPR
4
Show member pathways
12.03 GH1 GHRL IGF1 LEP POMC
6
Show member pathways
11.96 GH1 GHR LEP LEPR PRL
7 11.78 ADIPOQ GH1 IGF1 LEP RETN
8 11.68 ADIPOQ IGF1 LEP
9 11.48 GH1 GHR IGF1
10 11.33 LEP LEPR PRL
11
Show member pathways
11.22 GH1 GHR PRL
12
Show member pathways
11.06 LEP LEPR POMC
13 10.94 ADIPOQ AGRP LEP LEPR NPY POMC
14 10.32 CRH POMC

GO Terms for Anorexia Nervosa

Cellular components related to Anorexia Nervosa according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 ADIPOQ AGRP CCK CRH GH1 GHR
2 neuronal cell body GO:0043025 9.65 AGRP CCK CRH GHR HTR2A
3 extracellular region GO:0005576 9.55 ADIPOQ AGRP BDNF CCK CRH GH1
4 endosome lumen GO:0031904 9.32 GH1 PRL
5 growth hormone receptor complex GO:0070195 9.16 GH1 GHR

Biological processes related to Anorexia Nervosa according to GeneCards Suite gene sharing:

(show all 49)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 CCK CRH GHRH HTR2A IGF1 LEP
2 response to drug GO:0042493 9.95 ADIPOQ COMT CRH HTR2A PRL SLC6A4
3 response to ethanol GO:0045471 9.91 ADIPOQ CRH LEP PRL
4 neuropeptide signaling pathway GO:0007218 9.88 AGRP NPY POMC PYY
5 movement of cell or subcellular component GO:0006928 9.87 IGF1 NPY PYY
6 response to estradiol GO:0032355 9.87 GH1 LEP PRL SLC6A4
7 regulation of blood pressure GO:0008217 9.86 LEP NPY POMC
8 response to insulin GO:0032868 9.85 AGRP LEP RETN
9 glucose metabolic process GO:0006006 9.85 ADIPOQ GHRL LEP
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.84 GH1 IGF1 LEP
11 female pregnancy GO:0007565 9.84 COMT CRH LEP PRL
12 response to nutrient GO:0007584 9.83 ADIPOQ LEP PRL SLC6A4
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.82 GH1 GHR IGF1
14 feeding behavior GO:0007631 9.8 AGRP NPY PYY
15 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 9.79 GH1 GHR LEP
16 hormone-mediated signaling pathway GO:0009755 9.77 AGRP GHR GHRL
17 regulation of multicellular organism growth GO:0040014 9.76 GHR IGF1 PRL
18 circadian rhythm GO:0007623 9.72 ADIPOQ AGRP LEP PRL SLC6A4
19 energy reserve metabolic process GO:0006112 9.71 LEP LEPR
20 positive regulation of glycolytic process GO:0045821 9.7 HTR2A IGF1
21 negative regulation of gluconeogenesis GO:0045721 9.7 ADIPOQ LEPR
22 insulin-like growth factor receptor signaling pathway GO:0048009 9.7 GHR IGF1
23 central nervous system neuron development GO:0021954 9.7 LEP NPY
24 sexual reproduction GO:0019953 9.69 LEP LEPR
25 parturition GO:0007567 9.69 CRH PRL
26 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 9.69 GH1 GHR IGF1
27 behavior GO:0007610 9.68 HTR2A NPY
28 positive regulation of growth hormone secretion GO:0060124 9.67 GHRH GHRL
29 regulation of feeding behavior GO:0060259 9.67 AGRP LEPR
30 leptin-mediated signaling pathway GO:0033210 9.67 LEP LEPR
31 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.67 GH1 GHR PRL
32 positive regulation of multicellular organism growth GO:0040018 9.67 GH1 GHR GHRH GHRL
33 growth hormone receptor signaling pathway GO:0060396 9.66 GH1 GHR
34 negative regulation of appetite GO:0032099 9.65 CCK LEP
35 growth hormone secretion GO:0030252 9.65 GHRH GHRL
36 regulation of bone remodeling GO:0046850 9.65 LEP LEPR
37 positive regulation of corticotropin secretion GO:0051461 9.64 CRH GHRL
38 bone mineralization involved in bone maturation GO:0035630 9.63 IGF1 LEP
39 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.63 GH1 GHRH IGF1
40 positive regulation of appetite GO:0032100 9.62 GHRL NPY
41 positive regulation of cortisol secretion GO:0051464 9.62 CRH GHRL
42 negative regulation of glucagon secretion GO:0070093 9.6 CRH LEP
43 regulation of appetite GO:0032098 9.58 NPY POMC PYY
44 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.56 CRH GHRL
45 eating behavior GO:0042755 9.56 AGRP CCK LEP PYY
46 bone growth GO:0098868 9.55 LEP LEPR
47 positive regulation of JAK-STAT cascade GO:0046427 9.46 GH1 GHR LEP PRL
48 adult feeding behavior GO:0008343 9.26 AGRP GHRL LEP NPY
49 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.1 ADIPOQ CCK GH1 GHR HTR2A IGF1

Molecular functions related to Anorexia Nervosa according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.73 ADIPOQ AGRP CRH LEP NPY POMC
2 growth factor activity GO:0008083 9.71 BDNF GH1 IGF1 LEP
3 G-protein coupled receptor binding GO:0001664 9.46 GHRL NPY POMC PYY
4 hormone activity GO:0005179 9.4 ADIPOQ CCK CRH GH1 GHRL IGF1
5 prolactin receptor binding GO:0005148 9.37 GH1 PRL
6 neuropeptide hormone activity GO:0005184 9.35 AGRP CCK CRH NPY PYY
7 growth hormone-releasing hormone activity GO:0016608 9.32 GHRH GHRL

Sources for Anorexia Nervosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....